- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Synonyms :
Class :
150
mg
Orally
twice a day
Interstitial Lung Diseases with a Chronic Fibrosing Progressive Phenotype
150 mg orally 2 times a day
Interstitial Lung Disease with associated Systemic Sclerosis
150 mg orally 2 times a day
Dose Adjustments
Dosage Modifications
Dose adjustments as a result of adverse reactions
the adverse reactions may need a dosage reduction or just a temporary interruption till the specificed adverse reaction get resolves.
Resume at 150 mg every 12 hours, or 100 mg every 12 hours, which can then be increased to the maximum dose (150 mg q12hr)
If 100 mg every 12 hours is not tolerated, the medication should be discontinued.
liver enzymes Elevated
AST/ALT levels more than 3 to 5 times the ULN without the signs for severe liver damage: Reduce or discontinue medication to 100 mg BID; after LFTs returns to normal, can reintroduce at 100 mg twice a day, which can be later increased to 150 mg twice a day.
AST/ALT levels more than 5times ULN or greater than 3times ULN with signs and symptoms for severe liver damage: Discontinue
Renal impairment
Mild and moderate: dosage adjustment is not necessary
ESRD or Severe (CrCl less than 30 mL/min): Not recommended Hepatic impairment
Mild (Child Pugh score A): 100 mg orally every 12hours
Moderate and severe (Child Pugh score B or C): usually Not recommended
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nintedanib
may have an increasingly adverse effect when combined with nintedanib
may have an increasingly adverse effect when combined with nintedanib
may have an increasingly adverse effect when combined with nintedanib
may have an increasingly adverse effect when combined with nintedanib
may have an increasingly adverse effect when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
Letrozole may enhance the serum concentration of nintedanib
Anastrozole may enhance the serum concentration of nintedanib
may enhance the serum concentration when combined with nintedanib